Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

被引：0
|
作者：
Podder, Vivek
Ranjan, Tulika
Bardhan, Mainak
McCracken, Andrea
Hurmiz, Charlie
Ganiyani, Mohammad Arfat
Ahmad, Shahzaib
Mahtani, Reshma L.
Ahluwalia, Manmeet Singh
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Guardian Res Network, Spartanburg, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [42] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [43] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [44] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [45] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Rupert Bartsch
    Anna Sophie Berghoff
    Julia Furtner
    Maximilian Marhold
    Elisabeth Sophie Bergen
    Sophie Roider-Schur
    Angelika Martina Starzer
    Heidrun Forstner
    Beate Rottenmanner
    Karin Dieckmann
    Zsuzsanna Bago-Horvath
    Helmuth Haslacher
    Georg Widhalm
    Aysegül Ilhan-Mutlu
    Christoph Minichsdorfer
    Thorsten Fuereder
    Thomas Szekeres
    Leopold Oehler
    Birgit Gruenberger
    Christian F. Singer
    Ansgar Weltermann
    Rainer Puhr
    Matthias Preusser
    Nature Medicine, 2022, 28 : 1840 - 1847
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
    Vaz Batista, M.
    Perez-Garcia, J. M.
    Llombart Cussac, A.
    Cortez, P.
    Ruiz Borrego, M.
    De la Haba, J.
    Cejalvo, J. M.
    Racca, F.
    Servitja, S.
    Blanch, S.
    Lema, L.
    Galan Garmaje, M.
    Fernandez-Abad, M.
    Fernandez, A.
    Iranzo, V.
    Gonzalez-Santiago, S.
    Gion, M.
    Nave, M.
    Cortes, J.
    Braga, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S509 - S510
  • [47] Trastuzumab deruxtecan: Defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?
    Bartsch, Rupert
    Preusser, Matthias
    NEURO-ONCOLOGY, 2024, 26 (12) : 2157 - 2158
  • [48] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
    Hurvitz, S. A.
    Kim, S. -B.
    Chung, W. -P.
    Im, S. -A.
    Park, Y. H.
    Hegg, R.
    Kim, M. -H.
    Tseng, L. -M.
    Petry, V.
    Chung, C. -F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Egorov, A.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Tecson, K.
    Verma, S.
    Cortes, J.
    ESMO OPEN, 2024, 9 (05)
  • [49] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [50] Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
    Onishi, Mai
    Shimoi, Tatsunori
    Kitadai, Rui
    Tokura, Momoko
    Yazaki, Shu
    Sumiyoshi-Okuma, Hitomi
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Syosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1423 - S1423
12345